127. 前頭側頭葉変性症
[臨床試験数:74,薬物数:83(DrugBank:28),標的遺伝子数:29,標的パスウェイ数:99

Searched query = "Frontotemporal lobar degeneration", "Frontotemporal dementia", "Semantic dementia"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
52 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2019-004066-18-GB
(EUCTR)
03/12/202025/09/2020A Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of AL001 in FTDA Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of AL001 in Individuals at Risk for or With Frontotemporal Dementia Due to Heterozygous Mutations in the Progranulin Gene Frontotemporal Dementia
MedDRA version: 21.1;Level: PT;Classification code 10068968;Term: Frontotemporal dementia;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: AL001
Product Code: AL001
INN or Proposed INN: not available
Other descriptive name: AL001
Alector Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
180Phase 3Portugal;United States;Spain;United Kingdom;Italy;Switzerland;France;Canada;Belgium;Australia;Germany;Netherlands;Sweden
2EUCTR2019-004066-18-SE
(EUCTR)
06/10/202010/06/2020A Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of AL001 in FTDA Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of AL001 in Individuals at Risk for or With Frontotemporal Dementia Due to Heterozygous Mutations in the Progranulin Gene Frontotemporal Dementia
MedDRA version: 21.1;Level: PT;Classification code 10068968;Term: Frontotemporal dementia;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: AL001
Product Code: AL001
INN or Proposed INN: not available
Other descriptive name: AL001
Alector Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
180Phase 3Portugal;United States;Spain;Italy;Switzerland;United Kingdom;France;Canada;Belgium;Australia;Germany;Netherlands;Sweden
3EUCTR2019-004066-18-NL
(EUCTR)
02/09/202003/03/2020A Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of AL001 in FTDA Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of AL001 in Individuals at Risk for or With Frontotemporal Dementia Due to Heterozygous Mutations in the Progranulin Gene Frontotemporal Dementia
MedDRA version: 21.1;Level: PT;Classification code 10068968;Term: Frontotemporal dementia;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: AL001
Product Code: AL001
INN or Proposed INN: not available
Other descriptive name: AL001
Alector Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
180Phase 3United States;Portugal;France;Canada;Spain;Belgium;Australia;Germany;Netherlands;United Kingdom;Italy;Sweden
4EUCTR2019-004066-18-BE
(EUCTR)
31/07/202026/05/2020A Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of AL001 in FTDA Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of AL001 in Individuals at Risk for or With Frontotemporal Dementia Due to Heterozygous Mutations in the Progranulin Gene Frontotemporal Dementia
MedDRA version: 21.1;Level: PT;Classification code 10068968;Term: Frontotemporal dementia;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: AL001
Product Code: AL001
INN or Proposed INN: not available
Other descriptive name: AL001
Alector Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
180Phase 3United States;Portugal;France;Canada;Spain;Belgium;Australia;Netherlands;Germany;United Kingdom;Italy;Sweden
5NCT04408625
(ClinicalTrials.gov)
July 30, 202021/5/2020Phase 1/2 Clinical Trial of PR006 in Patients With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN)A Phase 1/2 Ascending Dose Study to Evaluate the Safety and Effects on Progranulin Levels of PR006A in Patients With Fronto-Temporal Dementia With Progranulin Mutations (FTD-GRN)Frontotemporal DementiaBiological: PR006;Drug: Methylprednisolone;Drug: Sirolimus;Drug: PrednisonePrevail TherapeuticsNULLRecruiting30 Years80 YearsAll15Phase 1;Phase 2United States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT04374136
(ClinicalTrials.gov)
July 23, 202023/4/2020A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of AL001 in Individuals at Risk for or With Frontotemporal Dementia Due to Heterozygous Mutations in the Progranulin GeneFrontotemporal DementiaDrug: AL001;Drug: PlaceboAlector Inc.NULLRecruiting18 Years85 YearsAll180Phase 3United States;Australia;Belgium;Canada;France;Germany;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom
7EUCTR2019-004066-18-DE
(EUCTR)
06/07/202020/02/2020A Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of AL001 in FTDA Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of AL001 in Individuals at Risk for or With Frontotemporal Dementia Due to Heterozygous Mutations in the Progranulin Gene Frontotemporal Dementia
MedDRA version: 21.1;Level: PT;Classification code 10068968;Term: Frontotemporal dementia;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: AL001
Product Code: AL001
INN or Proposed INN: not available
Other descriptive name: AL001
Alector Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
180Phase 3Portugal;United States;Spain;Italy;Switzerland;United Kingdom;France;Canada;Belgium;Australia;Germany;Netherlands;Sweden
8EUCTR2019-004066-18-PT
(EUCTR)
29/05/202021/02/2020A Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of AL001 in FTDA Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of AL001 in Individuals at Risk for or With Frontotemporal Dementia Due to Heterozygous Mutations in the Progranulin Gene Frontotemporal Dementia
MedDRA version: 21.1;Level: PT;Classification code 10068968;Term: Frontotemporal dementia;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: AL001
Product Code: AL001
INN or Proposed INN: not available
Other descriptive name: AL001
Alector Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
180Phase 3Portugal;United States;Spain;Italy;Switzerland;United Kingdom;France;Canada;Belgium;Australia;Germany;Netherlands;Sweden
9EUCTR2019-004066-18-ES
(EUCTR)
22/04/202006/03/2020A Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of AL001 in FTDA Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of AL001 in Individuals at Risk for or With Frontotemporal Dementia Due to Heterozygous Mutations in the Progranulin Gene Frontotemporal Dementia
MedDRA version: 21.1;Level: PT;Classification code 10068968;Term: Frontotemporal dementia;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: AL001
Product Code: AL001
INN or Proposed INN: not available
Other descriptive name: AL001
Alector Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
180Phase 3United States;Portugal;France;Canada;Belgium;Spain;Australia;Netherlands;Germany;United Kingdom;Italy;Sweden
10NCT04220021
(ClinicalTrials.gov)
January 10, 20203/1/2020Safety and Therapeutic Potential of the FDA-approved Drug Metformin for C9orf72 ALS/FTDA Single-Center, Open Label Study to Assess the Safety and Tolerability of Metformin in Subjects With C9orf72 Amyotrophic Lateral Sclerosis Over 24 Weeks of TreatmentC9orf72 Amyotrophic Lateral Sclerosis (ALS);Frontotemporal DementiaDrug: MetforminUniversity of FloridaNULLRecruiting18 Years80 YearsAll18Phase 2United States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11EUCTR2019-000138-20-GB
(EUCTR)
18/11/201921/05/2019An Open-Label Study to Evaluate Safety of long-term AL001 dosing in FTDA Phase 2, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AL001 in Heterozygous Carriers of Granulin or C9ORF72 Mutations Causative of Frontotemporal Dementia Frontotemporal Dementia
MedDRA version: 21.1;Level: PT;Classification code 10068968;Term: Frontotemporal dementia;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: AL001
Product Code: AL001
INN or Proposed INN: not available
Other descriptive name: AL001
Alector Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
32Phase 2United States;Canada;Netherlands;Germany;Italy;United Kingdom
12EUCTR2019-000138-20-DE
(EUCTR)
08/10/201927/05/2019An Open-Label Study to Evaluate Safety of long-term AL001 dosing in FTDA Phase 2, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AL001 in Heterozygous Carriers of Granulin or C9ORF72 Mutations Causative of Frontotemporal Dementia Frontotemporal Dementia
MedDRA version: 21.1;Level: PT;Classification code 10068968;Term: Frontotemporal dementia;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: AL001
Product Code: AL001
INN or Proposed INN: not available
Other descriptive name: AL001
Alector Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
40Phase 2United States;Canada;Netherlands;Germany;United Kingdom;Italy
13NCT03987295
(ClinicalTrials.gov)
September 27, 201914/5/2019A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2)A Phase 2, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AL001 in Heterozygous Carriers of Granulin or C9orf72 Mutations Causative of Frontotemporal DementiaFrontotemporal DementiaDrug: AL001Alector Inc.NULLRecruiting18 Years85 YearsAll40Phase 2United States;Canada;Germany;Italy;Netherlands;United Kingdom
14EUCTR2019-000138-20-NL
(EUCTR)
20/09/201906/06/2019An Open-Label Study to Evaluate Safety of long-term AL001 dosing in FTDA Phase 2, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AL001 in Heterozygous Carriers of Granulin or C9ORF72 Mutations Causative of Frontotemporal Dementia Frontotemporal Dementia
MedDRA version: 21.1;Level: PT;Classification code 10068968;Term: Frontotemporal dementia;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: AL001
Product Code: AL001
INN or Proposed INN: not available
Other descriptive name: AL001
Alector Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
40Phase 2United States;Canada;Germany;Netherlands;United Kingdom;Italy
15NCT04115384
(ClinicalTrials.gov)
September 9, 20192/10/2019Intranasal Insulin in Frontotemporal Dementia (FTD)A Single Center Feasibility Study of Intranasal Insulin in Frontotemporal Dementia NIFT-DFrontotemporal Dementia, Behavioral VariantDrug: Novolin-R insulinHealthPartners InstituteNULLRecruiting41 Years89 YearsAll12Phase 2United States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
16NCT04489017
(ClinicalTrials.gov)
June 1, 201913/4/2020Palmitoylethanolamide Combined With Luteoline in Frontotemporal Dementia Patients. A Randomized Controlled TrialPalmitoylethanolamide Combined With Luteoline in Frontotemporal Dementia Patients. A Randomized Controlled TrialFrontotemporal DementiaDietary Supplement: PEA-LUT;Dietary Supplement: PLACEBOI.R.C.C.S. Fondazione Santa LuciaNULLRecruiting40 Years80 YearsAll50N/AItaly
17NCT03636204
(ClinicalTrials.gov)
September 14, 201812/7/2018A First in Human Study in Healthy Volunteers and in Participants With Frontotemporal Dementia With Granulin (GRN) MutationA First in Human Phase 1 Study in Healthy Volunteers and in Participants With Frontotemporal Dementia (FTD) With Granulin MutationHealthy;Frontotemporal DementiaBiological: AL001;Other: PlaceboAlector Inc.NULLCompleted18 Years80 YearsAll64Phase 1United States;Canada;United Kingdom;Netherlands
18NCT03658135
(ClinicalTrials.gov)
September 12, 201813/8/2018BIIB092 in Primary Tauopathies: CBS, nfvPPA, sMAPT, and TESA Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Parallel Cohort Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of Intravenously Infused BIIB092 in Patients With Four Different Primary Tauopathy SyndromesPrimary Tauopathies;Corticobasal Degeneration Syndrome;Frontotemporal Lobar Degeneration With Tau Inclusions;MAPT Mutation Carriers, Symptomatic;Traumatic Encephalopathy Syndrome;Nonfluent Aphasia, ProgressiveDrug: BIIB092;Other: PlaceboUniversity of California, San FranciscoNULLTerminated35 Years80 YearsAll22Phase 1United States
19NCT03510572
(ClinicalTrials.gov)
June 4, 201817/4/2018Evaluation of [18F]PI-2620 as a Potential Positron Emission Computed Tomography Radioligand for Imaging Tau Protein in the BrainClinical Evaluation of [18F]PI-2620 Positron Emission Computed Tomography for Imaging Tau Protein in Patients With Tauopathies and Healthy Volunteers: Phase 0 StudyHealthy Volunteer;Alzheimer Disease;Frontotemporal Dementia;Parkinson DiseaseDrug: [18F]PI-2620Asan Medical CenterKorea Health Industry Development InstituteCompleted40 Years80 YearsAll20Early Phase 1Korea, Republic of
20NCT03260920
(ClinicalTrials.gov)
January 31, 201819/7/2017Intranasal Oxytocin for Frontotemporal DementiaA Phase 2 Clinical Trial of Intranasal Oxytocin for Frontotemporal DementiaFrontotemporal DementiaDrug: SyntocinonLawson Health Research InstituteWeston Brain Institute;Canadian Institutes of Health Research (CIHR);Berry ConsultantsRecruiting30 Years80 YearsAll112Phase 2United States;Canada
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
21NCT03625128
(ClinicalTrials.gov)
January 2, 201812/7/201818F-PM-PBB3 PET Study in Tauopathy Including Alzheimer's Disease, Other Dementias and Normal ControlsPhase 0 Evaluation of Clinical and Neuroimage (18F-PM-PBB3 PET) Study in Tauopathy Including Alzheimer's Disease, Other Dementias and Normal ControlsAlzheimer's Disease;Cortical Basal Syndrome;Frontotemporal Dementia;Progressive Supranuclear Palsy;Vascular Cognitive ImpairmentDrug: F-18Chang Gung Memorial HospitalNULLCompleted20 Years90 YearsAll36Early Phase 1Taiwan
22NCT02707978
(ClinicalTrials.gov)
September 30, 20177/4/2015F 18 T807 Tau PET Imaging of Frontotemporal Dementia (FTD)F 18 T807 Tau PET Imaging of Frontotemporal DementiaAlzheimer DiseaseDrug: F 18 T807Tammie L. S. Benzinger, MD, PhDNULLWithdrawn18 YearsN/AAll0Phase 2United States
23NCT03272230
(ClinicalTrials.gov)
September 6, 20173/8/2017Assessment of Apathy in a Real-life Situation, With a Video and Sensors-based SystemAssessment of Apathy in a Real-life Situation, With a Video and Sensors-based System in Healthy Subject and Patient With Cerebral DiseaseApathy;Frontotemporal Dementia;Parkinson Disease;Depressive SymptomsBehavioral: ECOCAPTURE;Behavioral: Cognitive and Behavioral experimental tasks;Diagnostic Test: Neuropsychological assessment;Behavioral: ICM_APATHY_TASKS;Other: MRI;Biological: Neurohormonal mechanisms;Diagnostic Test: Supplementary Neuropsychological Assessment - Parkinson's DiseaseInstitut National de la Santé Et de la Recherche Médicale, FranceNULLRecruiting40 Years85 YearsAll135N/AFrance
24NCT03545126
(ClinicalTrials.gov)
August 21, 201712/3/2018Human CNS Tau Kinetics in TauopathiesHuman CNS Tau Kinetics in TauopathiesProgressive Supranuclear Palsy (PSP);Corticobasal Degeneration (CBD);Frontotemporal Dementia (FTD MAPT Mutation)Other: 13C6 LeucineWashington University School of MedicineAssociation of Frontotemporal Degeneration;Tau ConsortiumRecruiting18 YearsN/AAll32United States
25NCT03174938
(ClinicalTrials.gov)
May 15, 201728/5/2017The Swedish BioFINDER 2 StudyThe Swedish BioFINDER 2 StudyDementia;Alzheimer Disease;Parkinson Disease;Lewy Body Disease;Parkinson-Dementia Syndrome;Frontotemporal Degeneration;Semantic Dementia;Progressive Nonfluent Aphasia;Progressive Supranuclear Palsy;Corticobasal Degeneration;Multiple System Atrophy;Mild Cognitive ImpairmentDiagnostic Test: Flutemetamol F18 Injection;Diagnostic Test: [18F]-RO6958948;Diagnostic Test: Elecsys (Roche) Abeta42, Ttau and Ptau;Diagnostic Test: Lumipulse (Fujirebio) Abeta42, Ttau and PtauSkane University HospitalLund UniversityRecruiting20 Years100 YearsAll1505N/ASweden
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
26NCT03040713
(ClinicalTrials.gov)
April 11, 201731/1/2017Flortaucipir PET Imaging in Subjects With FTD18F-AV-1451 PET Imaging in Subjects With Frontotemporal DementiaFrontotemporal DementiaDrug: Flortaucipir F18;Procedure: Brain PET scanAvid RadiopharmaceuticalsNULLCompleted18 YearsN/AAll16Phase 1United States
27EUCTR2017-000094-36-SE
(EUCTR)
31/03/201730/01/2017The BioFINDER 2 study - improved diagnostics and increased understanding of the underlying mechanisms of cognitive disordersThe BioFINDER 2 study - improved diagnostics and increased understanding of the pathophysiology of cognitive disorders Neurodegenerative disorders with Tau-pathology; including, but not limited to, Alzheimers disease, progressive supranuclear palsy,frontotemporal dementia, corticobasal degeneration and mild cognitive impairment.
MedDRA version: 19.1;Level: PT;Classification code 10053643;Term: Neurodegenerative disorder;System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 19.1;Classification code 10012267;Term: Dementia;Classification code 10067889;Term: Dementia with Lewy bodies;Level: HLGT;Classification code 10028037;Term: Movement disorders (incl parkinsonism);Classification code 10012271;Term: Dementia Alzheimer's type;Level: HLT;Classification code 10001897;Term: Alzheimer's disease (incl subtypes);Level: LLT;Classification code 10009846;Term: Cognitive impairment;Classification code 10048598;Term: Cognitive disorders;Classification code 10001896;Term: Alzheimer's disease;Classification code 10012285;Term: Dementia due to Pick's disease;Classification code 10036813;Term: Progressive supranuclear palsy;Classification code 10074616;Term: Prodromal Alzheimer's;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]
Product Name: 18F-RO6958948
Trade Name: Vizamyl (flutemetamol(F-18))
Product Name: Vizamyl
Skåne University HospitalNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Phase 2Sweden
28NCT02862210
(ClinicalTrials.gov)
January 27, 20177/8/2016Low-Dose Lithium for the Treatment of Behavioral Symptoms in Frontotemporal DementiaLow-Dose Lithium for the Treatment of Behavioral Symptoms in Frontotemporal DementiaFrontotemporal Dementia (FTD)Drug: Lithium Carbonate;Drug: PlaceboColumbia UniversityAlzheimer's Drug Discovery FoundationRecruiting40 Years85 YearsAll60Phase 2United States
29EUCTR2015-005604-29-NL
(EUCTR)
16/11/201620/01/2016Imaging of tau in patients with dementiaTau-imaging in tauopathies; Alzheimer’s disease and non-AD dementias - TITAN Dementia inducing Alzheimer's disease, Frontotemporal dementia (FTD) and Lewy Body Dementia (DLB)
MedDRA version: 20.0;Level: PT;Classification code 10012271;Term: Dementia Alzheimer's type;System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 20.0;Level: LLT;Classification code 10057095;Term: Diffuse Lewy body disease;System Organ Class: 100000072901
MedDRA version: 20.0;Classification code 10068968;Term: Frontotemporal dementia;Classification code 10012283;Term: Dementia due to other general medical conditions;System Organ Class: 100000014717;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: 18F-AV-1451
INN or Proposed INN: not applicable
Other descriptive name: T807
VU University Medical CenterNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Phase 2Netherlands
30NCT02676843
(ClinicalTrials.gov)
April 201615/1/2016Tau PET Imaging With 18F-AV-1451 in Subjects With MAPT MutationsTau PET Imaging With 18F-AV-1451 in Subjects With MAPT MutationsFrontotemporal Lobar Degeneration (FTLD);Frontotemporal Dementia (FTD);TauopathiesDrug: 18F-AV-1451Columbia UniversityNational Institute of Neurological Disorders and Stroke (NINDS)Completed18 YearsN/AAll7Phase 2United States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
31EUCTR2014-002013-37-NL
(EUCTR)
24/03/201613/07/2015An open-label extension study evaluating the safety and tolerability of leuco-methylthioninium dihydromesylate (LMTM) in subjects with Alzheimer's Disease or a rare form of dementia (Behavioral Variant Frontotemporal Dementia) who have completed an earlier Phase trialAn Open-Label, Extension Study of the Effects of Leuco-methylthioninium bis(hydromethanesulfonate) in Subjects with Alzheimer’s Disease or Behavioral Variant Frontotemporal Dementia Alzheimer’s Disease and behavioral variant Frontotemporal Dementia
MedDRA version: 19.0;Level: PT;Classification code 10068968;Term: Frontotemporal dementia;System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 19.0;Level: LLT;Classification code 10001896;Term: Alzheimer's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Leuco-methylthioninium bis(hydromethanesulfonate)
Product Code: LMTM/TRx0237
INN or Proposed INN: N/A
Other descriptive name: N,N,N',N'-tetramethyl-10H-phenothiazine-3,7-diaminium bis(methanesulfonate)
TauRx Therapeutics LtdNULLNot RecruitingFemale: yes
Male: yes
966Phase 3United States;Taiwan;Finland;Spain;Russian Federation;United Kingdom;France;Canada;Malaysia;Belgium;Singapore;Romania;Croatia;Australia;Bulgaria;Netherlands;Germany;Korea, Republic of
32EUCTR2014-002013-37-BE
(EUCTR)
03/06/201531/03/2015An open-label extension study evaluating the safety and tolerability of leuco-methylthioninium dihydromesylate (LMTM) in subjects with Alzheimer's Disease or a rare form of dementia (Behavioral Variant Frontotemporal Dementia) who have completed an earlier Phase trialAn Open-Label, Extension Study of the Effects of Leuco-methylthioninium bis(hydromethanesulfonate) in Subjects with Alzheimer’s Disease or Behavioral Variant Frontotemporal Dementia Alzheimer’s Disease and behavioral variant Frontotemporal Dementia
MedDRA version: 18.1;Level: PT;Classification code 10068968;Term: Frontotemporal dementia;System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 18.1;Level: LLT;Classification code 10001896;Term: Alzheimer's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Leuco-methylthioninium bis(hydromethanesulfonate)
Product Code: LMTM/TRx0237
INN or Proposed INN: N/A
Other descriptive name: N,N,N',N'-tetramethyl-10H-phenothiazine-3,7-diaminium bis(methanesulfonate)
TauRx Therapeutics LtdNULLNot RecruitingFemale: yes
Male: yes
1400Phase 3United States;Taiwan;Finland;Spain;Russian Federation;United Kingdom;Italy;France;Canada;Poland;Malaysia;Belgium;Singapore;Romania;Croatia;Australia;Bulgaria;Netherlands;Germany;Korea, Republic of
33EUCTR2014-002013-37-FI
(EUCTR)
11/05/201525/03/2015An open-label extension study evaluating the safety and tolerability of leuco-methylthioninium dihydromesylate (LMTM) in subjects with Alzheimer's Disease or a rare form of dementia (Behavioral Variant Frontotemporal Dementia) who have completed an earlier Phase trialAn Open-Label, Extension Study of the Effects of Leuco-methylthioninium bis(hydromethanesulfonate) in Subjects with Alzheimer’s Disease or Behavioral Variant Frontotemporal Dementia Alzheimer’s Disease and behavioral variant Frontotemporal Dementia
MedDRA version: 19.0;Level: PT;Classification code 10068968;Term: Frontotemporal dementia;System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 19.0;Level: LLT;Classification code 10001896;Term: Alzheimer's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Leuco-methylthioninium bis(hydromethanesulfonate)
Product Code: LMTM/TRx0237
INN or Proposed INN: N/A
Other descriptive name: N,N,N',N'-tetramethyl-10H-phenothiazine-3,7-diaminium bis(methanesulfonate)
TauRx Therapeutics LtdNULLNot RecruitingFemale: yes
Male: yes
966Phase 3United States;Taiwan;Finland;Spain;Russian Federation;United Kingdom;France;Canada;Belgium;Malaysia;Singapore;Romania;Croatia;Australia;Netherlands;Germany;Korea, Republic of
34EUCTR2014-002013-37-HR
(EUCTR)
04/03/201531/03/2015An open-label extension study evaluating the safety and tolerability of leuco-methylthioninium dihydromesylate (LMTM) in subjects with Alzheimer's Disease or a rare form of dementia (Behavioral Variant Frontotemporal Dementia) who have completed an earlier Phase trialAn Open-Label, Extension Study of the Effects of Leuco-methylthioninium bis(hydromethanesulfonate) in Subjects with Alzheimer’s Disease or Behavioral Variant Frontotemporal Dementia Alzheimer’s Disease and behavioral variant Frontotemporal Dementia
MedDRA version: 19.0;Level: PT;Classification code 10068968;Term: Frontotemporal dementia;System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 19.0;Level: LLT;Classification code 10001896;Term: Alzheimer's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Leuco-methylthioninium bis(hydromethanesulfonate)
Product Code: LMTM/TRx0237
INN or Proposed INN: N/A
Other descriptive name: N,N,N',N'-tetramethyl-10H-phenothiazine-3,7-diaminium bis(methanesulfonate)
TauRx Therapeutics LtdNULLNot RecruitingFemale: yes
Male: yes
966Phase 3United States;Taiwan;Finland;Spain;Russian Federation;United Kingdom;France;Canada;Argentina;Malaysia;Belgium;Singapore;Romania;Croatia;Australia;Bulgaria;Netherlands;Germany;Korea, Republic of
35EUCTR2014-002013-37-ES
(EUCTR)
13/02/201516/12/2014An open-label extension study evaluating the safety and tolerability of leuco-methylthioninium dihydromesylate (LMTM) in subjects with Alzheimer's Disease or a rare form of dementia (Behavioral Variant Frontotemporal Dementia) who have completed an earlier Phase trialAn Open-Label, Extension Study of the Effects of Leuco-methylthioninium bis(hydromethanesulfonate) in Subjects with Alzheimer?s Disease or Behavioral Variant Frontotemporal Dementia Alzheimer?s Disease and behavioral variant Frontotemporal Dementia
MedDRA version: 17.1;Level: PT;Classification code 10068968;Term: Frontotemporal dementia;System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 17.1;Level: LLT;Classification code 10001896;Term: Alzheimer's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Leuco-methylthioninium bis(hydromethanesulfonate)
Product Code: LMTM/TRx0237
INN or Proposed INN: N/A
Other descriptive name: N,N,N',N'-tetramethyl-10H-phenothiazine-3,7-diaminium bis(methanesulfonate)
TauRx Therapeutics LtdNULLNot RecruitingFemale: yes
Male: yes
1400Phase 3United States;Taiwan;Finland;Spain;Russian Federation;Italy;United Kingdom;France;Canada;Argentina;Poland;Malaysia;Belgium;Singapore;Romania;Croatia;Australia;Bulgaria;Netherlands;Germany;Korea, Republic of
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
36EUCTR2014-001315-40-IT
(EUCTR)
03/12/201410/10/2014Florbetapir-PET scan in subjects with a known mutation for autosomal dominant Alzheimer's Disease taking part in the ItalianDIAfN studyAmyloid Imaging in the Italian Network for autosomal dominant Alzheimer’s disease and frontotemporal lobar degeneration (ItalianDIAfN)” - Amyloid-PET in ItalianDIAfN Autosomal Dominant Alzheimer's Disease
MedDRA version: 17.0;Level: LLT;Classification code 10001896;Term: Alzheimer's disease;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Amyvid
Product Name: Florbetapir (18F)
Product Code: Florbetapir (18F)
INN or Proposed INN: florbetapir (18F)
Other descriptive name: N/A
IRCCS Istituto Centro San Giovanni di Dio FatebenefratelliNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Italy
37EUCTR2014-002013-37-GB
(EUCTR)
06/10/201420/08/2014An open-label extension study evaluating the safety and tolerability of leuco-methylthioninium dihydromesylate (LMTM) in subjects with Alzheimer's Disease or a rare form of dementia (Behavioral Variant Frontotemporal Dementia) who have completed an earlier Phase trial An Open-Label, Extension Study of the Effects of Leuco-methylthioninium bis(hydromethanesulfonate) in Subjects with Alzheimer’s Disease or Behavioral Variant Frontotemporal Dementia Alzheimer’s Disease and behavioral variant Frontotemporal Dementia
MedDRA version: 19.0;Level: PT;Classification code 10068968;Term: Frontotemporal dementia;System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 19.0;Level: LLT;Classification code 10001896;Term: Alzheimer's disease;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
TauRx Therapeutics LtdNULLNot Recruiting Female: yes
Male: yes
966Phase 3United States;Taiwan;Finland;Spain;Russian Federation;United Kingdom;France;Canada;Malaysia;Belgium;Singapore;Romania;Croatia;Australia;Bulgaria;Netherlands;Germany;Korea, Republic of
38EUCTR2014-000422-38-SE
(EUCTR)
19/09/201405/08/2014A study evaluating the diagnostic accuracy of [18F]-AV-1451 PET to detect and distinguish neurodegenerative disorders characterized by cerebral accumulation of the protein tauAn open-label study evaluating the diagnostic accuracy of [18F]-AV-1451 PET to detect and distinguish neurodegenerative disorders characterized by cerebral accumulation of tau Neurodegenerative disorders with Tau-pathology; including Alzheimer's disease, progressive supranuclear palsy, frontotemporal dementia, corticobasal degeneration and important differential diagnostic conditions.
MedDRA version: 17.0;Level: HLT;Classification code 10001897;Term: Alzheimer's disease (incl subtypes);System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 17.0;Level: PT;Classification code 10053643;Term: Neurodegenerative disorder;Level: LLT;Classification code 10009846;Term: Cognitive impairment;Classification code 10001896;Term: Alzheimer's disease;Classification code 10012285;Term: Dementia due to Pick's disease;Classification code 10012267;Term: Dementia;Classification code 10067889;Term: Dementia with Lewy bodies;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]
Product Name: 18F-AV-1451Skåne University Hospital, Region SkåneNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Sweden
39NCT02245568
(ClinicalTrials.gov)
August 201427/8/2014Open-Label Study of Leuco-methylthioninium Bis(Hydromethanesulfonate) (LMTM) in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD)An Open-Label, Extension Study of the Effects of LMTM in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD)Alzheimer's Disease;Behavioral Variant Frontotemporal DementiaDrug: LMTMTauRx Therapeutics LtdNULLTerminatedN/AN/AAll913Phase 3United States;Australia;Belgium;Canada;Croatia;Finland;France;Germany;Korea, Republic of;Malaysia;Netherlands;Romania;Russian Federation;Singapore;Spain;Taiwan;United Kingdom;Argentina;Bulgaria;Italy;Poland
40NCT01937013
(ClinicalTrials.gov)
September 12, 20133/9/2013Impact of Emotional Mimicry and Oxytocin on Frontotemporal DementiaImpact of Emotional Mimicry and Oxytocin on Frontotemporal DementiaFrontotemporal DementiaDrug: Intranasal oxytocin;Drug: Saline Nasal MistLawson Health Research InstituteCanadian Institutes of Health Research (CIHR)Completed30 Years85 YearsAll52Phase 2Canada
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
41NCT01626378
(ClinicalTrials.gov)
May 201320/6/2012Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)Behavioral Variant Frontotemporal Dementia (bvFTD)Drug: TRx0237;Drug: PlaceboTauRx Therapeutics LtdNULLCompletedN/A79 YearsAll220Phase 3United States;Australia;Canada;Croatia;Germany;Italy;Netherlands;Poland;Romania;Singapore;Spain;United Kingdom;Argentina;Bulgaria;Finland
42EUCTR2012-004328-40-IT
(EUCTR)
01/03/201323/11/2012study of neuroinflammation in pathologies like Alzheimer, mild cognitive impairment, dementia and SLAIMAGING OF NEUROINFLAMMATION IN NEURODEGENERATIVE DISEASES mild cognitive impairment, Alzheimer disease,frontotemporal dementia, SLA
MedDRA version: 14.1;Level: LLT;Classification code 10050727;Term: RI scan;System Organ Class: 100000004848;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: NA
Product Code: (R)-[N-metil-11C1-PK11195(PK)
OSPEDALE S. RAFFAELE DI MILANONULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Italy
43NCT00604591
(ClinicalTrials.gov)
July 201119/1/2008Effects of Tolcapone on Frontotemporal DementiaInvestigation of the Dopamine System in Frontotemporal DementiaFrontotemporal Lobar DegenerationDrug: Tolcapone;Drug: PlaceboColumbia UniversityNational Institute of Neurological Disorders and Stroke (NINDS)Completed40 Years85 YearsAll28Phase 2United States
44JPRN-UMIN000003683
2010/06/0131/05/2010The efficacy of ferulic acid in the treatment of dementia Alzheimer's Disease, Dementia of Lewy Body,Vascular Dementia, Frontotemporal DementiaTaking of Ferulic Acid for 6 months followed by Not taking of Ferulic Acid for 6 months.

Not taking of Ferulic Acid for 6 months followed by taking of Ferulic Acid for 6 months.
Shimane University HospitalNULLComplete: follow-up complete20years-old90years-oldMale and Female50Not selectedJapan
45NCT01056965
(ClinicalTrials.gov)
January 201021/1/2010Davunetide (AL-108) in Predicted Tauopathies - Pilot StudyA 12 Week Randomized, Double Blind, Placebo-Controlled Pilot Study of Davunetide (NAP, AL-108) in Predicted TauopathiesPredicted Tauopathies, Including;Progressive Supranuclear Palsy;Frontotemporal Dementia With Parkinsonism Linked to Chromosome 17;Corticobasal Degeneration Syndrome;Progressive Nonfluent AphasiaDrug: davunetide (AL-108, NAP);Drug: Placebo nasal sprayUniversity of California, San FranciscoNULLCompleted40 Years85 YearsAll12Phase 1United States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
46NCT01002300
(ClinicalTrials.gov)
September 200923/10/2009Oxytocin and Social Cognition in Frontotemporal DementiaInvestigation of the Effects of Intranasal Oxytocin on Cognition and Emotion Processing in Frontotemporal DementiaFrontotemporal Dementia;Pick's DiseaseDrug: intranasal oxytocinLawson Health Research InstituteThe Alzheimer Society London and MiddlesexCompleted30 Years80 YearsBoth24N/ACanada
47NCT01890343
(ClinicalTrials.gov)
September 200927/6/2013Imaging Characteristics of Florbetapir 18F in Patients With Frontotemporal Dementia, Alzheimer's Disease and Normal Controls.A Study Evaluating the Imaging Characteristics of Florbetapir 18F (18F-AV-45) in Patients With Frontotemporal Dementia Compared to Patients With Alzheimer's Disease and Normal Controls.Alzheimer's Disease;Frontotemporal DementiaDrug: florbetapir 18F;Drug: 18F-FDGAvid RadiopharmaceuticalsNULLCompleted45 YearsN/AAll34Phase 2United Kingdom
48EUCTR2008-003597-18-GB
(EUCTR)
28/05/200914/04/2009Amyloid imaging in Alzheimer’s disease, frontotemporal dementia and healthy volunteersA study evaluating the imaging characteristics of 18F-AV-45 in patients with frontotemporal dementia compared to patients with Alzheimer's disease and normal controls Use of 18F-AV-45 positron emission tomography as early diagnostic technique in frontal lobe dementia and Alzheimer's disease.
MedDRA version: 14.0;Level: PT;Classification code 10061816;Term: Diagnostic procedure;System Organ Class: 10022891 - Investigations
Avid Radiopharmaceuticals, IncNULLNot Recruiting Female: yes
Male: yes
40Phase 2United Kingdom
49NCT00950430
(ClinicalTrials.gov)
April 200829/7/2009Imaging of Brain Amyloid Plaques in the Aging PopulationBrain Amyloid Imaging With Pittsburgh Compound B in Normal Aging, Mild Cognitive Impairment, and DementiaAlzheimer's Disease;Dementia With Lewy Bodies;Frontotemporal Dementia;Vascular DementiaDrug: Pittsburgh Compound B (C-11 PiB);Drug: F-18 FDG;Drug: Tau (18-F-AV-1451)Mayo ClinicNational Institute on Aging (NIA)Enrolling by invitation30 Years100 YearsAll2500Phase 4United States
50NCT00545974
(ClinicalTrials.gov)
October 200716/10/2007Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal DementiaA Prospective, Randomized, Multi-Center, Double-Blind, 26 Week, Placebo-Controlled Trial of Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal DementiaFrontal Lobe Dementia;Frontotemporal Lobe Dementia;Semantic DementiaDrug: memantine;Drug: Placebo pillUniversity of California, San FranciscoForest LaboratoriesCompleted40 Years80 YearsAll81Phase 4United States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
51NCT00376051
(ClinicalTrials.gov)
September 200613/9/2006Serotonergic Function and Behavioural and Psychological Symptoms of Frontotemporal DementiaSerotonergic Function and Behavioural and Psychological Symptoms of Frontotemporal DementiaFrontotemporal DementiaDrug: CitalopramSunnybrook Health Sciences CentreAlzheimer Society of CanadaCompleted18 YearsN/AAll22Phase 4Canada
52NCT00127114
(ClinicalTrials.gov)
September 20053/8/2005Amantadine for the Treatment of Behavioral Disturbance in Frontotemporal Dementia (FTD)Amantadine for the Treatment of Behavioral Disturbance in Frontotemporal Dementia (FTD)DementiaDrug: Amantadine;Drug: PlaceboJohns Hopkins UniversityNULLWithdrawn40 Years90 YearsAll0Phase 4United States